• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

    4/11/25 4:05:00 PM ET
    $NXPL
    $OPK
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXPL alert in real time by email

    The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities for Future US-Produced Products Including its Florida Sunshine Brand of Vitamins and Supplements Due to Tariff Impact

    COCONUT GROVE, Fla., April 11, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global e-Commerce provider, today provided an update on the impact of current United States/China tariffs on its e-Commerce development program as a result of China's escalation in tariffs placed on US-produced goods imported into the country. This condition is expected to have a material impact on anticipated sales of US products into China.

    NextPlat Corp. logo (PRNewsfoto/NextPlat Corp.)

    The Company plans to pause certain initiatives within its e-Commerce development program which was launched in April 2023 to help U.S.-based businesses reach the vast Chinese consumer market through major online platforms like Alibaba's Tmall. This includes the introduction of a new line of vitamins and supplements under the Florida Sunshine brand name, since these offerings would be subject to the increased tariffs and would face significant import costs which Management believes will reduce its ability to compete with locally produced products. The Company is still reviewing opportunities to sell its Florida Sunshine products in other markets.

    The Company intends to continue selling OPKO Health Europe (OPKO), a subsidiary of OPKO Health, Inc. (NASDAQ:OPK), products in China including an array of nutraceuticals and supplements as well as adding products for pet care, all of which are not produced in the United States and as such, are not subject to additional tariffs.

    For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X.

    About NextPlat Corp

    NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the Company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care LLC.

    Forward-Looking Statements

    Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services, or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to introduce new products and services and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

    Media and Investor Contact for NextPlat Corp:

    Michael Glickman

    MWGCO, Inc.

    917-397-2272

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-provides-statement-on-us-tariff-impact-on-its-e-commerce-development-program-302426823.html

    SOURCE NextPlat Corp.

    Get the next $NXPL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NXPL
    $OPK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $NXPL
    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Opko Health

      Analyst initiated coverage of Opko Health with a rating of Neutral

      4/25/25 8:32:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opko Health upgraded by Barrington Research with a new price target

      Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00

      6/29/23 9:11:26 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Opko Health with a new price target

      H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00

      12/15/22 8:08:28 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXPL
    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & Chairman Frost Phillip Md Et Al bought $169,712 worth of shares (125,000 units at $1.36) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/10/25 5:07:15 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $184,650 worth of shares (125,000 units at $1.48) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/8/25 5:34:21 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & Chairman Frost Phillip Md Et Al bought $164,850 worth of shares (100,000 units at $1.65) (SEC Form 4)

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      4/1/25 5:21:45 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXPL
    $OPK
    SEC Filings

    See more

    $NXPL
    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NextPlat Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NextPlat Corp (0001058307) (Filer)

      6/26/25 1:25:12 PM ET
      $NXPL
      Telecommunications Equipment
      Telecommunications
    • SEC Form S-8 filed by NextPlat Corp

      S-8 - NextPlat Corp (0001058307) (Filer)

      6/10/25 4:00:46 PM ET
      $NXPL
      Telecommunications Equipment
      Telecommunications
    • NextPlat Corp filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NextPlat Corp (0001058307) (Filer)

      5/30/25 12:04:56 PM ET
      $NXPL
      Telecommunications Equipment
      Telecommunications
    • NextPlat Issues Interim CEO Update Shareholder Letter

      COCONUT GROVE, Fla., June 30, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today issued the following Interim CEO Update Shareholder Letter: To Our Shareholders: As interim CEO of NextPlat and on behalf of our Board of Directors and management team, I am writing to you to provide an update on our company and the actions being taken to drive the business forward. In the month since the un

      6/30/25 8:01:00 AM ET
      $NXPL
      $OPK
      Telecommunications Equipment
      Telecommunications
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

      MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and propriet

      6/25/25 11:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

      MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment and as a weekly subcutaneous injection for patients with

      6/25/25 8:00:00 AM ET
      $ENTX
      $OPK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $NXPL
    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO & Chairman Frost Phillip Md Et Al

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:08:32 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman & CTO Hsiao Jane Ph D

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:07:08 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman and President Zerhouni Elias A.

      4 - OPKO HEALTH, INC. (0000944809) (Issuer)

      5/29/25 5:05:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXPL
    $OPK
    Financials

    Live finance-specific insights

    See more
    • NextPlat Reports First Quarter 2025 Results

      Company Reports $14.5M in Q1 Revenue; Operating Expenses Decline 26% as Expected, with Continued Focus on Cost Reduction, Efficiency Improvements, and Strategic Planning Amid Rising Drug Prices and Potential Tariff Impacts COCONUT GROVE, Fla., May 15, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced the financial results for the quarter-ended March 31, 2025, reflecting the performance of its e-Commerce and Healthcare Operations. "The first quarter results reflect a series of challenges

      5/15/25 7:30:00 AM ET
      $NXPL
      Telecommunications Equipment
      Telecommunications
    • NextPlat to Release First Quarter 2025 Results on Thursday, May 15, 2025

      Investor Conference Call Scheduled for Thursday, May 15, 2025 at 8:30 a.m. Eastern COCONUT GROVE, Fla., May 6, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it will release its financial results for the quarter ended March 31, 2025 before market open on May 15, 2025. NextPlat's Executive Chairman and CEO, Charles M. Fernandez, Chief Financial Officer, Cecile Munnik and President and CEO of Global Operations, David Phipps, will host a conference call on May 15th at 8:30 a.m. EDT to disc

      5/6/25 8:01:00 AM ET
      $NXPL
      Telecommunications Equipment
      Telecommunications
    • OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference's laboratory testing businesses focused on oncology and oncology-related clinical testing services for up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. BioReference will continue to

      4/30/25 4:05:00 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXPL
    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

      SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/15/24 4:39:33 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by OPKO Health Inc.

      SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

      11/13/24 4:30:24 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

      SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

      11/12/24 4:54:06 PM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXPL
    $OPK
    Leadership Updates

    Live Leadership Updates

    See more
    • OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

      WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

      9/23/24 8:00:00 AM ET
      $OPK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextPlat Announces Results of Annual Meeting of Stockholders

      Business Combination with Progressive Care Inc. Approved with Anticipated Closing Date of October 1, 2024 COCONUT GROVE, Fla., Sept. 16, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW))) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced the results of the Company's Special Annual Meeting of Stockholders ("the Annual Meeting") held on September 13, 2024. At the Annual Meeting, shareholders were asked to vote on six proposals, the most notable being the following: A proposal to approve and adopt the Merger Agreement and Plan of Reorganization p

      9/16/24 5:35:00 PM ET
      $NXPL
      Telecommunications Equipment
      Telecommunications
    • Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

      NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

      9/15/22 4:05:00 PM ET
      $OPK
      $TALK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Nursing Services